$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000115903615000092 Filed on November 09, 2015

Income Statement

Concept	2015 Q3	2014 Q3
Revenue	$31.85M	$14.61M
YoY Change	118.08%	-8.79%
Cost Of Revenue	$6.180M	$5.141M
YoY Change	20.21%	652.71%
Gross Profit	$4.197M	$4.476M
YoY Change	-6.23%	-52.09%
Gross Profit Margin	13.18%	30.64%
Selling, General & Admin	$10.23M	$8.587M
YoY Change	19.09%	5.56%
% of Gross Profit	243.65%	191.85%
Research & Development	$27.61M	$19.90M
YoY Change	38.72%	-22.52%
% of Gross Profit	657.87%	444.68%
Depreciation & Amortization	$400.0K	$500.0K
YoY Change	-20.0%	66.67%
% of Gross Profit	9.53%	11.17%
Operating Expenses	$37.84M	$28.49M
YoY Change	32.8%	-15.77%
Operating Profit	-$23.24M	-$19.03M
YoY Change	22.13%	2.88%
Interest Expense	$1.301M	$1.376M
YoY Change	-5.45%	61.88%
% of Operating Profit
Other Income/Expense, Net	$78.00K	$122.0K
YoY Change	-36.07%	134.62%
Pretax Income	-$24.46M	-$20.30M
YoY Change	20.49%	5.18%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$28.95M	-$20.28M
YoY Change	42.73%	5.12%
Net Earnings / Revenue	-90.87%	-138.85%
Basic Earnings Per Share	-$0.19	-$0.16
Diluted Earnings Per Share	-$0.19	-$163.7K
COMMON SHARES
Basic Shares Outstanding	126.9M shares	124.0M shares
Diluted Shares Outstanding	126.9M shares

Balance Sheet

Concept	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.7M	$134.5M
YoY Change	-8.03%	105.97%
Cash & Equivalents	$71.51M	$46.38M
Short-Term Investments	$52.20M	$88.10M
Other Short-Term Assets	$9.900M	$8.900M
YoY Change	11.24%	-2.2%
Inventory	$11.10M	$6.916M
Prepaid Expenses
Receivables	$8.392M	$8.275M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$153.1M	$158.6M
YoY Change	-3.47%	54.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.686M	$3.249M
YoY Change	-17.33%	-34.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.000M	$2.800M
YoY Change	7.14%	16.67%
Total Long-Term Assets	$5.644M	$6.026M
YoY Change	-6.34%	-17.76%
TOTAL ASSETS
Total Short-Term Assets	$153.1M	$158.6M
Total Long-Term Assets	$5.644M	$6.026M
Total Assets	$158.7M	$164.6M
YoY Change	-3.58%	49.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.437M	$4.342M
YoY Change	2.19%	-22.35%
Accrued Expenses	$18.93M	$15.02M
YoY Change	25.98%	-27.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.70M	$10.08M
YoY Change	55.82%	68.76%
Total Short-Term Liabilities	$44.85M	$34.59M
YoY Change	29.65%	-12.7%
LONG-TERM LIABILITIES
Long-Term Debt	$34.10M	$39.80M
YoY Change	-14.32%	51.33%
Other Long-Term Liabilities	$3.746M	$2.759M
YoY Change	35.77%	199.42%
Total Long-Term Liabilities	$3.746M	$2.759M
YoY Change	35.77%	199.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.85M	$34.59M
Total Long-Term Liabilities	$3.746M	$2.759M
Total Liabilities	$48.60M	$37.35M
YoY Change	30.11%	-7.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$487.0M	-$445.2M
YoY Change	9.4%	23.63%
Common Stock	$518.8M	$485.1M
YoY Change	6.93%	36.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.80M	$39.94M
YoY Change
Total Liabilities & Shareholders Equity	$158.7M	$164.6M
YoY Change	-3.58%	49.46%

Cashflow Statement

Concept	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$28.95M	-$20.28M
YoY Change	42.73%	5.12%
Depreciation, Depletion And Amortization	$400.0K	$500.0K
YoY Change	-20.0%	66.67%
Cash From Operating Activities	-$17.00M	-$13.20M
YoY Change	28.79%	6.45%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$300.0K
YoY Change	0.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$20.70M	$3.000M
YoY Change	590.0%
Cash From Investing Activities	$20.20M	$2.700M
YoY Change	648.15%	-1000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K	800.0K
YoY Change	-37.5%	-65.22%
NET CHANGE
Cash From Operating Activities	-17.00M	-13.20M
Cash From Investing Activities	20.20M	2.700M
Cash From Financing Activities	500.0K	800.0K
Net Change In Cash	3.700M	-9.700M
YoY Change	-138.14%	-6.73%
FREE CASH FLOW
Cash From Operating Activities	-$17.00M	-$13.20M
Capital Expenditures	-$300.0K	-$300.0K
Free Cash Flow	-$16.70M	-$12.90M
YoY Change	29.46%	6.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128014034	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC.
	dei	Trading Symbol TradingSymbol	HALO
CY2014Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1266000	USD
CY2015Q3	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1230000	USD
CY2014Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2133000	USD
CY2015Q3	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2433000	USD
CY2014Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	6361000	USD
CY2015Q3	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	5463000	USD
CY2014Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4383000	USD
CY2015Q3	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	7017000	USD
CY2014Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	480000	USD
CY2015Q3	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	679000	USD
CY2014Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2112000	USD
CY2015Q3	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3914000	USD
CY2015Q3	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2015Q3	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2014Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	611000	USD
CY2015Q3	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	734000	USD
CY2014Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6339000	USD
CY2015Q3	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	7181000	USD
CY2014Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2380000	USD
CY2015Q3	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3120000	USD
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3003000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4437000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9760000	USD
CY2015Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9126000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9149000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8392000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1062000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-699000	USD
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14441000	USD
CY2015Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19605000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13961000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18926000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9219000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9983000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	491694000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	518647000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4176000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11065000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5553000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15588000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1610000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	885000	USD
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9800000	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9600000	shares
CY2014Q4	us-gaap	Assets Assets	165977000	USD
CY2015Q3	us-gaap	Assets Assets	158734000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	161321000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	153090000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	116919000	USD
CY2015Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	119765000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	74234000	USD
CY2015Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	52204000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	43100000	USD
CY2015Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	11
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46375000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71514000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19018000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10125000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125721000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	127811000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125721000	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	127811000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	128000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20329000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63164000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24420000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36508000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5141000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16585000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6180000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20818000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	33632000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	104142000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	44017000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	115747000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	54634000	USD
CY2015Q3	us-gaap	Deferred Revenue DeferredRevenue	50033000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5789000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	47267000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	44244000	USD
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1300000	USD
CY2015Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1304000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1218000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5923000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5614000	USD
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1693000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6011000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-822000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-757000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-418000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4600000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	746000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4695000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	32000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-200000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-98000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	1376000	USD
	us-gaap	Interest Expense InterestExpense	4203000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	1301000	USD
	us-gaap	Interest Expense InterestExpense	3899000	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1400000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	4200000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	3900000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	646000	USD
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1140000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	6406000	USD
CY2015Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9494000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165977000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	553000	USD
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	467000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	11101000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	11896000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5207000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158734000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24331000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	44851000	USD
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2094000	USD
CY2015Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2205000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	28896000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	49860000	USD
CY2015Q3	us-gaap	Long Term Debt LongTermDebt	34094000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	15699000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11367000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	112030000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-46433000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	20644000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-46579000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-21886000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-20280000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-63101000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-24460000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36549000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19026000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59185000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23237000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32917000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2023000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3060000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2000000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2900000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	1535000	USD
CY2015Q3	us-gaap	Other Assets OtherAssets	520000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-49000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-63000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	40000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	41000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3167000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3746000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	122000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	287000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	78000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	267000	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1094000	USD
CY2015Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1516000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	89117000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	46360000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1132000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	726000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4317000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11348000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12337000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10143000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9879000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1205000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2458000	USD
CY2015Q3	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11367000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	43816000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	67730000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12170000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12669000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2951000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2686000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19904000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59968000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27611000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65490000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	paid in full during the three months ended March 31, 2015
CY2014Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450427000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-486976000	USD
CY2014Q3	us-gaap	Revenues Revenues	14606000	USD
	us-gaap	Revenues Revenues	44957000	USD
CY2015Q3	us-gaap	Revenues Revenues	20780000	USD
	us-gaap	Revenues Revenues	82830000	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	2895000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5382000	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	8274000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	21431000	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9617000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27679000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10301000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	32503000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8587000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27589000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10226000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29439000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41352000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	31799000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11065000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15588000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2100000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3300000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8400000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8800000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124041000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122157000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126921000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126127000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators’ proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> technology. rHuPH20 is also the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. When HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 works by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the cancer with increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 clinical testing for PEGPH20 in metastatic pancreatic cancer (Study 109-202), in Phase 1b clinical testing in non-small cell lung cancer (Study 107-201), and in Phase 1b clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regarding Enhanze, we currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxter Healthcare Corporation (predecessor to Baxalta Incorporated) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), and AbbVie, Inc. (“AbbVie”), with one product approved in the U.S. and three products approved for marketing in Europe from which we are receiving royalties and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-15-000092-index-headers.html	Edgar Link	pending
0001159036-15-000092-index.html	Edgar Link	pending
0001159036-15-000092.txt	Edgar Link	pending
0001159036-15-000092-xbrl.zip	Edgar Link	pending
ex101formofamendedandresta.htm	Edgar Link	pending
ex102formofstockoptionagre.htm	Edgar Link	pending
ex103formofrsaagreement.htm	Edgar Link	pending
ex104formofrsuagreement.htm	Edgar Link	pending
ex311q32015.htm	Edgar Link	pending
ex312q32015.htm	Edgar Link	pending
ex32q32015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-20150930.xml	Edgar Link	completed
halo-20150930.xsd	Edgar Link	pending
halo-20150930_cal.xml	Edgar Link	unprocessable
halo-20150930_def.xml	Edgar Link	unprocessable
halo-20150930_lab.xml	Edgar Link	unprocessable
halo-20150930_pre.xml	Edgar Link	unprocessable
halo3q2015-10q.htm	Edgar Link	pending
pipelineslide6nov2015a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q3 Form 10-Q Financial Statement

#000115903615000092 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q3 Form 10-Q Financial Statement

#000115903615000092 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo